| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892
We have previously described a mitoxantrone-resistant human breast carcinoma cell line, MCF7/MX, in which resistance was associated with a defect in the energy-dependent accumulation of mitoxantrone in the absence of P-glycoprotein overexpression (M. Nakagawa et al., Cancer Res. 52: 6175–6181, 1992). We now report that this cell line is highly cross-resistant to the camptothecin analogues topotecan (180-fold), 9-aminocamptothecin (120-fold), CPT-11 (56-fold), and SN38 (101-fold), but is only mildly cross-resistant to the parent compound camptothecin (3.2-fold) and 10,11-methylenedioxy-camptothecin (2.9-fold). Topotecan accumulation was decreased in MCF7/MX cells compared to parental MCF7/WT cells, and there was a corresponding reduction in topotecan-mediated stimulation of the enzyme/DNA complex formation in MCF7/MX cells compared to MCF7/WT cells. No overexpression of the multidrug resistance-associated protein was detected compared to parental MCF7/WT cells. Furthermore, both sensitive MCF7/WT and mitoxantrone-resistant MCF7/MX cells contain equal amounts of DNA topoisomerase I protein, and DNA relaxation activities were equal in both cell lines and inhibited to the same extent by topotecan and camptothecin. Thus, these results suggest a novel mechanism of resistance to topoisomerase I inhibitors in cancer cells.
1 To whom requests for reprints should be addressed, and presently at Department of Oncology, National Taiwan University Hospital, 7, Chung-Shan South Road, Taipei, Taiwan, 100.
2 Present address: Sealy Center for Molecular Science, University of Texas Medical Branch, Galveston, TX 77555.
3 Present address: Laboratory of Diagnostic Oncology, Division of Molecular Medicine, Wadsworth Center for Laboratories and Research, Albany, NY 12201-0509.
Received 6/ 5/95. Accepted 8/ 3/95.
This article has been cited by other articles:
|
|
 |
|
  F. R. Luo, P. V. Paranjpe, A. Guo, E. Rubin, and P. Sinko Intestinal Transport of Irinotecan in Caco-2 Cells and MDCK II Cells Overexpressing Efflux Transporters Pgp, cMOAT, and MRP1 Drug Metab. Dispos., July 1, 2002; 30(7): 763 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Honjo, C. A. Hrycyna, Q.-W. Yan, W. Y. Medina-Perez, R. W. Robey, A. van de Laar, T. Litman, M. Dean, and S. E. Bates Acquired Mutations in the MXR/BCRP/ABCP Gene Alter Substrate Specificity in MXR/BCRP/ABCP-overexpressing Cells Cancer Res., September 1, 2001; 61(18): 6635 - 6639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Vanhoefer, A. Harstrick, W. Achterrath, S. Cao, S. Seeber, and Y. M. Rustum Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview J. Clin. Oncol., March 1, 2001; 19(5): 1501 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Erlichman, S. A. Boerner, C. G. Hallgren, R. Spieker, X.-Y. Wang, C. D. James, G. L. Scheffer, M. Maliepaard, D. D. Ross, K. C. Bible, et al. The HER Tyrosine Kinase Inhibitor CI1033 Enhances Cytotoxicity of 7-Ethyl-10-hydroxycamptothecin and Topotecan by Inhibiting Breast Cancer Resistance Protein-mediated Drug Efflux Cancer Res., January 1, 2001; 61(2): 739 - 748. [Abstract] [Full Text]
|
|
|
|
|
|
E. L. Volk, K. Rohde, M. Rhee, J. J. McGuire, L. A. Doyle, D. D. Ross, and E. Schneider Methotrexate Cross-Resistance in a Mitoxantrone-selected Multidrug-resistant MCF7 Breast Cancer Cell Line Is Attributable to Enhanced Energy-dependent Drug Efflux Cancer Res., July 1, 2000; 60(13): 3514 - 3521. [Abstract] [Full Text]
|
|
|
|
|
|
M. Brangi, T. Litman, M. Ciotti, K. Nishiyama, G. Kohlhagen, C. Takimoto, R. Robey, Y. Pommier, T. Fojo, and S. E. Bates Camptothecin Resistance: Role of the ATP-binding Cassette (ABC), Mitoxantrone-resistance Half-Transporter (MXR), and Potential for Glucuronidation in MXR-expressing Cells Cancer Res., December 1, 1999; 59(23): 5938 - 5946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Allen, R. F. Brinkhuis, J. Wijnholds, and A. H. Schinkel The Mouse Bcrp1/Mxr/Abcp Gene: Amplification and Overexpression in Cell Lines Selected for Resistance to Topotecan, Mitoxantrone, or Doxorubicin Cancer Res., September 1, 1999; 59(17): 4237 - 4241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Maliepaard, M. A. van Gastelen, L. A. de Jong, D. Pluim, R. C. A. M. van Waardenburg, M. C. Ruevekamp-Helmers, B. G. J. Floot, and J. H. M. Schellens Overexpression of the BCRP/MXR/ABCP Gene in a Topotecan-selected Ovarian Tumor Cell Line Cancer Res., September 1, 1999; 59(18): 4559 - 4563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-S. Chen, T. Furukawa, T. Sumizawa, K. Ono, K. Ueda, K. Seto, and S.-I. Akiyama ATP-Dependent Efflux of CPT-11 and SN-38 by the Multidrug Resistance Protein (MRP) and Its Inhibition by PAK-104P Mol. Pharmacol., May 1, 1999; 55(5): 921 - 928. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. D. Ross, W. Yang, L. V. Abruzzo, W. S. Dalton, E. Schneider, H. Lage, M. Dietel, L. Greenberger, S. P. C. Cole, and L. A. Doyle Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitoxantrone-Selected Cell Lines J Natl Cancer Inst, March 3, 1999; 91(5): 429 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Hazlehurst, N. E. Foley, M. C. Gleason-Guzman, M. P. Hacker, A. E. Cress, L. W. Greenberger, M. C. De Jong, and W. S. Dalton Multiple Mechanisms Confer Drug Resistance to Mitoxantrone in the Human 8226 Myeloma Cell Line Cancer Res., March 1, 1999; 59(5): 1021 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. D. Reid, E. A. Kauh, and M.-A. Bjornsti Camptothecin Sensitivity Is Mediated by the Pleiotropic Drug Resistance Network in Yeast J. Biol. Chem., May 2, 1997; 272(18): 12091 - 12099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Kaufmann, P. A. Svingen, S. D. Gore, D. K. Armstrong, Y.-C. Cheng, and E. K. Rowinsky Altered Formation of Topotecan-Stabilized Topoisomerase I-DNA Adducts in Human Leukemia Cells Blood, March 15, 1997; 89(6): 2098 - 2104. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
